< Back to previous page

Project

The development of an off-the-shelf immunological combination therapy for glioblastoma multiforme

We will study the contribution of hypoxia-inducible factors (HIF) to innate immunosuppression in glioblastoma (GBM) in hypoxia. The capacity of HIF inhibitors combined with an immunostimulant to eliminate GBM cells will be studied in hypoxic cocultures of human GBM cells, natural killer cells and macrophages. This study will elucidate mechanisms of GBM-mediated immunosuppression and will generate valuable new insights for the development of novel efficacious immunotherapeutic strategies to treat GBM.
Date:1 Dec 2017 →  31 Dec 2018
Keywords:COMBINATION THERAPY, IMMUNOTHERAPY
Disciplines:Immunology, Morphological sciences, Oncology